Mensc Labs supplies high‑quality menstrual blood‑derived mesenchymal stem cells (MenSC‑Cell™) as an off‑the‑shelf product for research and product development. Each vial includes ISCT characterisation, anonymised donor health data, and validated trilineage differentiation, enabling reproducible studies in regenerative medicine and women's health. A forthcoming MenSC‑Exo™ line will add extracellular vesicle products with ISEV‑compliant reporting.
Funding
Funding not disclosed
Founders
Product
Problem
Researchers and product developers in regenerative medicine often face difficulty obtaining standardized, high‑quality menstrual blood‑derived mesenchymal stem cells (MenSCs) because existing sources require in‑house isolation, extensive donor screening, and validation, leading to variability and long lead times.
Solution
Mensc Labs supplies cryopreserved MenSCs (MenSC‑Cell™) as ready‑to‑use, research‑grade vials that include an ISCT characterisation report, anonymised donor health data, and validated trilineage differentiation results for each lot. The cells are available in defined quantities (1 million or 10 million cells) at a fixed price, eliminating the need for laboratories to perform their own isolation and quality control. By standardising processing and providing comprehensive documentation, Mensc Labs enables reproducible experiments and accelerates product development pipelines. An exosome product (MenSC‑Exo™) is scheduled for release in Q3 2026, with ISEV‑compliant characterisation and optional lyophilisation, expanding the portfolio for downstream therapeutic research.
Target Audience
Primary customers are academic laboratories, biotech firms, and pharmaceutical R&D teams developing regenerative therapies or conducting stem‑cell research that require consistent, well‑characterised MenSCs and related exosome products.
Features
- Cryopreserved MenSCs delivered in 1 M or 10 M cell vials (S$450 and S$1500 respectively)
- Full ISCT‑based phenotypic characterisation report for each lot
- Anonymised donor screening data covering age, menstrual health, and medical history
- Validated trilineage differentiation data confirming multipotency per batch
- Research‑use‑only designation with no requirement for in‑house cell isolation
- Upcoming MenSC‑Exo™ exosome product with ISEV‑compliant NTA, Western blot, and BCA assay reports
- Optional lyophilisation add‑on for exosome stability and ease of transport